Clinical Trial Update: Safety and Efficacy of ALLO-501 Anti-CD19 Allogeneic CAR T Cells in Adults With Relapsed/Refractory Large B Cell or Follicular Lymphoma [Phase 1]

View source ↗

Summary

Phase 1 trial results show safety and preliminary efficacy for ALLO-501, an allogeneic anti-CD19 CAR-T therapy, in adults with relapsed/refractory diffuse large…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma
• Follicular Lymphoma

Drugs mentioned

• ALLO-501

Snippet

Sponsor: Allogene Therapeutics | Conditions: Relapsed/Refractory Large B Cell Lymphoma, Relapsed/Refractory Follicular Lymphoma | Phase 1 | Status: COMPLETED